Solara Active Pharma Sciences Limited
All news and filings related to Solara Active Pharma Sciences Limited.
View all news & filings- Medium impact
Solara Active Pharma Sciences upgraded to 'Strong' ESG rating (Crisil ESG 63)
Solara Active Pharma Sciences Limited's ESG rating has been upgraded to Crisil ESG 63 ('Strong' category) for FY26, an increase from Crisil ESG 56 in FY25. The independent rating was announced on October 10, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Issues Final Reminder for Rights Issue Forfeiture
Solara Active Pharma Sciences Limited's Rights Issue Committee approved a Final Reminder-cum-Forfeiture Notice for holders of partly paid-up Rights Equity Shares who have not paid outstanding call money. The company is finalizing the notice for dispatch.
Read the summary - Low impact
Solara Active Pharma Sciences Files SEBI Reg 74(5) Certificate for Q2 FY27
Solara Active Pharma Sciences Limited filed a certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The company received confirmation from its Registrar and Share Transfer Agent, Cameo Corporate Services Limited, regarding the dematerialisation and listing of securities.
Read the summary - Low impact
Solara Active Pharma Sciences Reminds Shareholders to Update PAN and KYC Details
Solara Active Pharma Sciences is reminding shareholders with physical shares to update their PAN, KYC, and nomination details as per SEBI circular. The company dispatched reminder letters on September 26, 2026. Service requests will be on hold until documents are submitted. Dividends will be paid electronically.
Read the summary - Low impact
Solara Active Pharma Sciences Closes Trading Window from Oct 1, 2026
Solara Active Pharma Sciences Limited will close its trading window from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half-year ending September 30, 2026. The board meeting date for results declaration will be announced later.
Read the summary - Medium impact
Solara Pharma's AGM: All resolutions passed, including appointment of director and related party transactions.
Solara Active Pharma Sciences Limited's Ninth AGM on September 18, 2026, saw all resolutions passed. This included the adoption of FY26 financial statements, the appointment of Mr. Arun Kumar Pillai as Non-Executive Director, and approval for related party transactions up to ₹480 crore with Strides Pharma Science Limited.
Read the summary - Low impact
Solara Active Pharma Sciences Holds 9th AGM on Sep 18, 2026
Solara Active Pharma Sciences Limited conducted its 9th AGM on September 18, 2026. Key resolutions included adopting FY26 financial statements and approving material related party transactions up to ₹480 crores with Strides Pharma Science Limited. Voting results are expected by September 22, 2026.
Read the summary - Medium impact
Solara Active Pharma Sciences Receives Rectification Order, Tax Demand of ₹161.92 Crore Dropped
Solara Active Pharma Sciences received a Rectification Order from the Income Tax Department on August 08, 2026. The order rectifies a previous tax demand of ₹161.92 Crore, reducing it to Nil. This has no financial or operational impact on the company.
Read the summary - Low impact
Solara Active Pharma Sciences Releases BRSR for FY2025-26
Solara Active Pharma Sciences has released its Business Responsibility and Sustainability Report for FY2025-26. The report details the company's ESG performance, including its API manufacturing operations and export reach. Solara is committed to sustainability goals, aiming for reduced GHG emissions and increased renewable energy use.
Read the summary - Medium impact
Solara Active Pharma Sciences Announces 9th AGM on Sept 18, 2026, with E-voting
Solara Active Pharma Sciences will hold its 9th AGM on September 18, 2026, via VC/OAVM. Key agenda items include adopting FY26 financial statements, re-appointing a director, ratifying cost auditor remuneration of ₹4.75 Lakhs, and approving related party transactions up to ₹480 Crores with Strides Pharma Science Limited. E-voting is open from Sept 15-17, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Announces 9th AGM on Sep 18, 2026
Solara Active Pharma Sciences Limited will hold its 9th Annual General Meeting on September 18, 2026, via Video Conference. The AGM notice and annual report will be shared electronically with members.
Read the summary - Low impact
Solara Active Pharma Converts 2.79 Lakh Rights Shares to Fully Paid-Up
Solara Active Pharma Sciences Limited converted 2,79,582 partly paid-up Rights Equity Shares into fully paid-up shares on August 19, 2026. This action follows the receipt of pending call monies and will result in necessary corporate actions for listing and trading approvals.
Read the summary - Low impact
Solara Active Pharma Sciences: CIO Appointment Date Revised to Aug 17
Solara Active Pharma Sciences Limited revised the appointment date for its new Chief Information Officer (CIO), Mr. Ajit Manocha. His joining date has been rescheduled from August 10, 2026, to August 17, 2026, due to personal reasons.
Read the summary - High impact
Solara Active Pharma Sciences Q1 FY27 Earnings Call Transcript Released
Solara Active Pharma Sciences reported Q1 FY27 revenues of ₹384 crore (up 20% YoY) and PAT of ₹16.3 crore (up 55% YoY), with highest EBITDA/PAT in 18 quarters. Base business revenue grew 24% YoY to ₹307 crore. Net debt reduced by ₹135 crore to ₹479 crore. Company targets debt below ₹440 crore by March 2027.
Read the summary - Low impact
Solara Pharma Publishes Unaudited Financial Results for Q1 FY27
Solara Active Pharma Sciences Limited announced its unaudited financial results for the quarter ended June 30, 2026. The results were published in Business Standard and Pratahkal newspapers on July 24, 2026, and are available on the company's website.
Read the summary - Medium impact
Solara Active Pharma Sciences Q1 FY27 Results: Profit at ₹16.31 Cr.
Solara Active Pharma Sciences reported a consolidated profit after tax of ₹16.31 crore for the quarter ended June 30, 2026. Total consolidated income was ₹381.60 crore. Standalone profit after tax was ₹16.99 crore. The Board of Directors approved the results on July 23, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences uploads Q1 FY27 earnings call audio recording
Solara Active Pharma Sciences has uploaded the audio recording of its Q1 FY27 earnings call held on July 23, 2026. The call discussed the unaudited financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - Low impact
Solara Active Pharma Sciences: Monitoring Agency Report for Q1 FY27 Confirms No Deviation in Rights Issue Proceeds
Solara Active Pharma Sciences' Monitoring Agency Report for the quarter ended June 30, 2026, confirms no deviation in Rights Issue proceeds. The ₹449.95 crore Rights Issue funds were used for debt repayment and general corporate purposes. Unutilized funds amount to ₹8.32 crore.
Read the summary - Low impact
Solara Active Pharma Sciences: No Deviation in Rights Issue Fund Utilization for Q1 FY27
Solara Active Pharma Sciences confirms no deviation in the utilization of ₹442.73 Crores raised via Rights Issue for the quarter ended June 30, 2026. Funds were used for debt repayment and general corporate purposes. The Audit Committee approved the statement.
Read the summary - Low impact
Solara Appoints Ajit Manocha as Chief Information Officer (CIO)
Solara Active Pharma Sciences Limited appointed Mr. Ajit Manocha as Chief Information Officer (CIO) effective August 10, 2026. Mr. Manocha has over 33 years of experience in technology and life sciences transformation.
Read the summary - High impact
Solara Active Pharma Q1'27: Revenue Up 20% to ₹3,843 Mn, Highest EBITDA & PAT in 18 Quarters
Solara Active Pharma reported Q1'27 results with overall revenues up 20% YoY to ₹3,843 Mn. EBITDA rose 10% to ₹635 Mn and PAT increased 55% to ₹163 Mn, the highest in 18 quarters. Base business revenues grew 24% YoY to ₹3,077 Mn. Net debt reduced by ₹1,346 Mn to ₹4,795 Mn.
Read the summary - Low impact
Solara Active Pharma Sciences Board Approves Q1 FY27 Unaudited Financial Results
Solara Active Pharma Sciences' Board approved Unaudited Financial Results for Q1 FY27 ended June 30, 2026. The results include both standalone and consolidated statements, along with a limited review report from auditors. The details will be available on the company's website.
Read the summary - Low impact
Solara Active Pharma Sciences schedules conference call for Q1FY27 results on July 23, 2026
Solara Active Pharma Sciences will hold a conference call on July 23, 2026, at 4:00 PM IST to discuss Q1FY27 unaudited financial results. Key management, including MD & CEO Sandeep Rao and CFO Sarat Kumar, will be present.
Read the summary - Low impact
Solara Active Pharma Sciences Files SEBI Compliance Certificate for Q1 FY27
Solara Active Pharma Sciences Limited submitted a certificate for the quarter ended June 30, 2026, as per SEBI (Depositories and Participants) Regulations, 2018. The certificate was received from the company's Registrar and Share Transfer Agent.
Read the summary - Medium impact
Solara Pharma Issues Final Call Money Notice; Forfeiture Risk for Defaulting Shareholders
Solara Active Pharma Sciences has issued a final notice for outstanding call money on partly paid-up equity shares. Shareholders must pay the First Call (₹131.25) and Second Call (₹112.50) by July 27, 2026, to avoid forfeiture. Payment is due for both calls combined.
Read the summary - Low impact
Solara Pharma to Transfer Unclaimed Shares to IEPF by Sep 10, 2026
Solara Active Pharma Sciences Limited will transfer shares with unclaimed dividends from FY 2018-19 to the IEPF by September 10, 2026. Shareholders must claim their dividends before this date. Details are available on the company's website.
Read the summary - Medium impact
Solara Active Pharma Sciences Q4 FY26 Earnings Call Transcript Released
Solara Active Pharma Sciences released its Q4 FY26 earnings call transcript. The company reported its highest revenue, gross margins, and EBITDA in 8 quarters, with a 12% Q-o-Q revenue growth and 65% EBITDA growth. Strategic options for the ibuprofen business are being evaluated, with a resolution expected in two quarters. Debt was reduced by ₹158 crore in FY26.
Read the summary - Low impact
Solara Active Pharma Sciences Publishes Audited FY26 & Q4FY26 Financial Results
Solara Active Pharma Sciences Limited published its audited financial results for the year ended March 31, 2026, and unaudited results for the quarter ended March 31, 2026. The details were published in newspapers on May 16, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Q4 FY26 Earnings Call Audio Recording Uploaded
Solara Active Pharma Sciences has uploaded the audio recording of its Q4 FY26 earnings call held on May 15, 2026. The call discussed financial results for the quarter and year ended March 31, 2026. The recording is available on the company's website.
Read the summary - Low impact
Solara Active Pharma Sciences: No Deviation in Rights Issue Proceeds Utilization for Q4FY26
Solara Active Pharma Sciences Limited reported no deviation in the utilization of its Rights Issue proceeds for the quarter ended March 31, 2026. The Rights Issue raised ₹446.95 crore. As of the reporting date, ₹308.58 crore has been utilized, with ₹138.37 crore remaining unutilized.
Read the summary - Low impact
Solara Active Pharma Sciences Revises Whistle Blower Policy and Adopts Board Evaluation Policy
Solara Active Pharma Sciences Limited's Board adopted a new Board Evaluation Policy and amended its Whistle Blower Policy on May 15, 2026. Both updated policies are available on the company's website.
Read the summary - Low impact
Solara Active Pharma Sciences: No Deviation in Rights Issue Fund Utilization for Q4 FY26
Solara Active Pharma Sciences Limited reported no deviation in the utilization of funds from its Rights Issue for the quarter ended March 31, 2026. Total funds raised were ₹309.79 Crores. The Audit Committee noted the statement on May 15, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Re-appoints Grant Thornton as Internal Auditors for FY27
Solara Active Pharma Sciences Limited re-appointed Grant Thornton Bharat LLP as Internal Auditors and Mr. M K. Suryanarayanan as Cost Auditors for FY 2026-27. The appointments were approved by the Board of Directors on May 15, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Receives ₹129.94 Crore in Final Call Money
Solara Active Pharma Sciences received ₹129.94 crore from the second and final call on rights equity shares. The company approved converting 1.15 crore partly paid-up shares into fully paid-up shares with a face value of ₹10 each.
Read the summary - High impact
Solara Active Pharma Sciences Q4'26 Results: Revenue Up 40% YoY to ₹3,919 Million
Solara Active Pharma Sciences reported Q4'26 revenue of ₹3,919 million, a 40% YoY increase. The Base business showed strong growth with Q4'26 revenue at ₹3,070 million (up 36% YoY). The company is evaluating strategic options for its Ibuprofen business. Net debt is expected to reduce to ₹5,030 million by May 2026.
Read the summary - Medium impact
Solara Active Pharma Sciences Board Approves Audited FY26 Financial Results
Solara Active Pharma Sciences Limited's Board approved audited financial results for FY26 and Q4FY26. The company reported total income of ₹391.98 crore for Q4FY26 and ₹1,375.14 crore for FY26. Auditors issued an unmodified opinion on the financial statements.
Read the summary - Low impact
Solara Active Pharma Sciences Revises Investor Call Panel Member on May 15
Solara Active Pharma Sciences Limited has revised the panel for its investor conference call on May 15, 2026. The call will discuss audited financial results for Q4FY26. One management member cannot attend due to a scheduling conflict, but the call will proceed with remaining members.
Read the summary - Low impact
Solara Active Pharma Sciences Schedules Investor Conference Call for Q4FY26 Results on May 15
Solara Active Pharma Sciences will hold an investor conference call on Friday, May 15, 2026, at 3:00 PM IST to discuss audited financial results for Q4FY26 and FY26. Key management will attend.
Read the summary - Medium impact
Solara Pharma's Puducherry Facility Cleared by US FDA with VAI Classification, Inspection Closed
Solara Active Pharma Sciences' Puducherry facility successfully completed a US FDA inspection with a "Voluntary Action Indicated (VAI)" classification and has been "Closed". The inspection occurred from Feb 2-6, 2026, with observations being procedural.
Read the summary - Low impact
Solara Active Pharma Sciences Files SEBI Compliance Certificate for Q4 FY26
Solara Active Pharma Sciences Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate was received from Cameo Corporate Services Limited, the company's Registrar and Share Transfer Agent.
Read the summary - Medium impact
Solara Active Pharma Sciences issues Second and Final Call Money Notice
Solara Active Pharma Sciences Limited is making a Second and Final Call for ₹112.50 per partly paid-up equity share. The payment period is from April 23 to May 7, 2026. Advertisements were published on April 8, 2026.
Read the summary - Medium impact
Solara Active Pharma Sciences: Second & Final Call Notice Issued for Rights Equity Shares
Solara Active Pharma Sciences is issuing a Second and Final Call for partly paid rights equity shares. The call amount is ₹112.50 per share. The payment period is from April 23, 2026, to May 07, 2026. Trading in these partly paid shares has been suspended since April 02, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Closes Trading Window from April 1, 2026
Solara Active Pharma Sciences Limited will close its trading window from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. The date of the board meeting for results declaration will be announced later.
Read the summary - Low impact
Solara Active Pharma Sciences Announces Record Date for Second & Final Call
Solara Active Pharma Sciences Limited has set April 02, 2026, as the record date for its Second and Final Call on partly paid-up equity shares. The call amount is ₹112.50 per share.
Read the summary - Low impact
Solara Active Pharma Sciences Announces Special Window for Physical Share Transfer Requests
Solara Active Pharma Sciences Limited has announced a special window for re-lodging transfer requests for physical shares. This is in compliance with a SEBI circular dated January 30, 2026. The company has published notices in Business Standard and Pratahkal on March 25, 2026.
Read the summary - Low impact
Solara Active Pharma Sciences Announces Final Call for Rights Issue Shares
Solara Active Pharma Sciences approved a final call of ₹ 112.50 per equity share for partly-paid Rights Shares. The record date for this call is set for April 02, 2026. This action pertains to the Rights Issue initiated with a Letter of Offer dated May 09, 2024.
Read the summary - Low impact
Solara Active Pharma Sciences Fixes April 2, 2026, as Record Date for Final Call on Rights Shares
Solara Active Pharma Sciences Limited has set April 2, 2026, as the record date for its Second & Final call on partly-paid Rights Shares. The company will collect ₹112.50 per share, comprising ₹3 face value and ₹109.50 premium.
Read the summary - Low impact
Solara Active Pharma Sciences Announces Second & Final Call of ₹112.50 Per Share
Solara Active Pharma Sciences' Rights Issue Committee approved a Second & Final Call of ₹112.50 per equity share for partly-paid Rights Shares. The call, comprising ₹3 face value and ₹109.50 premium, is made under the May 09, 2024 Letter of Offer. April 02, 2026, is fixed as the Record Date for call notices.
Read the summary - Medium impact
Solara Pharma Receives ₹161.92 Crore Tax Demand Notice for AY 2019-20
Solara Active Pharma Sciences Limited received a tax demand notice of ₹161.92 Crores for Assessment Year 2019-20 due to disallowed expenses. The company plans to appeal the order, stating it does not expect a material financial impact.
Read the summary - Medium impact
Solara Pharma shareholders approve Mohanraj Sanjeevi as Whole-time Director
Solara Active Pharma Sciences Limited shareholders approved Mr. Mohanraj Sanjeevi's appointment as Whole-time Director. The resolution passed via remote e-voting. His tenure is three years from Jan 1, 2026, with ₹85 lakh fixed and ₹15 lakh variable annual pay.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio